This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: To assess cognitive abilities of healthy first-degree relatives of Ashkenazi patients with Parkinson disease (PD), carriers of the G2019S mutation in the LRRK2 gene.
Methods: In this observational study, 60 consecutive healthy first-degree relatives (aged 50.9 ± 6.2 years; 48% male; 30 G2019S carriers) were assessed using a computerized cognitive program, the Montreal Cognitive Assessment questionnaire, the Unified Parkinson's Disease Rating Scale Part III, and the Geriatric Depression Scale.
Results: G2019S carriers scored significantly lower on the computerized executive function index (p = 0.04) and on specific executive function tasks (Stroop test, p = 0.007).
Conclusion: Carrying the LRRK2 G2019S mutation was associated with lower executive performance in a population at risk for PD.
GLOSSARY
- AJ=
- Ashkenazi Jewish;
- EF=
- executive function;
- GDS=
- Geriatric Depression Scale;
- MoCA=
- Montreal Cognitive Assessment test;
- PD=
- Parkinson disease;
- RT=
- reaction time;
- UPDRS=
- Unified Parkinson's Disease Rating Scale
Footnotes
-
LRRK2 Ashkenazi Jewish Consortium coinvestigators are listed on the Neurology® Web site at www.neurology.org.
-
Study funding: Supported by grants from the Tel Aviv Sourasky Medical Center Grant of Excellence, Khan Foundation, Israel Science Foundation Heritage Legacy, the Michael J. Fox Foundation for Parkinson's Research, and the UMC ST Radboud, Nijmegen, the Netherlands. The LRRK2 Ashkenazi Jewish Consortium is funded by the Michael J. Fox Foundation, New York, New York.
-
Supplemental data at www.neurology.org
-
This work was performed in partial fulfillment of the requirements of a PhD degree of Avner Thaler, Sackler Faculty of Medicine, Tel Aviv University, Israel.
- Received December 9, 2011.
- Accepted April 19, 2012.
- Copyright © 2012 by AAN Enterprises, Inc.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Topics Discussed
Alert Me
Recommended articles
Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S LRRK2 carriers
Phenotype in parkinsonian and nonparkinsonian LRRK2 G2019S mutation carriers
Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium
Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers